Plasma and cerebrospinal fluid pharmacokinetics of vodobatinib, a neuroprotective c-Abl tyrosine kinase inhibitor for the treatment of Parkinson's disease
Parkinsonism & Related Disorders2023Vol. 108, pp. 105281–105281
Citations Over TimeTop 10% of 2023 papers
Ryan R. Walsh, Nitin K. Damle, Sanjay Mandhane, Steven P. Piccoli, Ravi S. Talluri, Damon Love, Siu‐Long Yao, Vikram Ramanathan, Orest Hurko
Abstract
Based on achieved CSF concentrations, the potential for c-Abl inhibition in the brain is substantially higher with vodobatinib than with nilotinib. The CSF PK profile of vodobatinib is suitable for determining if c-Abl inhibition will be neuroprotective in PD patients.
Related Papers
- → Pharmacokinetics of Four Tyrosine Kinase Inhibitors in Adult and Paediatric Chronic Myeloid Leukaemia Patients(2023)3 cited
- → ASH Annual Meeting 2012—Chronic Myeloid Leukemia Update(2013)1 cited
- → Pharmacokinetics of Four Tyrosine Kinase Inhibitors in Adult and Paediatric Chronic Myeloid Leukaemia Patients(2023)1 cited
- → Features of the etythropoesis upon treatment of chronic myeloid leukemia with tyrosine kinase inhibitor(2014)
- → Analysis of onset mechanism for tyrosine kinase inhibitor imatinib induced-left ventricular diastolic dysfunction(2020)